Information Provided By: 
Fly News Breaks for August 4, 2015
REGN
Aug 4, 2015 | 15:47 EDT
Brean Capital noted that Regeneron's U.S. Eylea sales "overwhelmingly" beat consensus in Q2. The firm raised its price target on the stock to $659 from $525 citing Eylea's continued strength and its belief that the company will do everything it can to change the treatment paradigm for patients that can be treated with Praluent.
News For REGN From the Last 2 Days
REGN
Apr 26, 2024 | 08:41 EDT
Oppenheimer analyst Hartaj Singh raised the firm's price target on Regeneron to $1,175 from $1,125 and keeps an Outperform rating on the shares ahead of the Q1 earnings report on May 2. Oppenheimer believes the areas of focus will be the status and dynamics of the Eylea High Dose launch, questions around the impending Dupixent COPD PDUFA, the status of the two oncology approvals expected in 2024, updates on various pipeline projects in immunology and oncology, and comments on capital allocation and financial planning by the new CFO at the company.
REGN
Apr 25, 2024 | 07:28 EDT
